DX 데이터 상품

데이터상품 제공 정보
데이터 제공 포맷	데이터 제공 방식	데이터 파일 용량
csv	다운로드	960.00 KB

데이터 메타 정보

상세정보 데이터
데이터셋명	이탈리아 상장사 재무정보 데이터	데이터 유형	csv
데이터 분야	기업정보	구축 데이터량	960.00 KB
구축기관	헤브론스타	데이터 갱신 일자	2023-12-20
데이터 개방 일자	2022-08-31	데이터 이용 기한	무기한
데이터 갱신 주기	-	버전	-
주요 키워드	해외기업빅데이터, 이탈리아상장사재무정보, 이탈리아기업재무정보, 이탈리아기업, 이탈리아상장사
벨류체인 키워드	기술개발, 인적자원, 제조, 마케팅, 물류유통, 서비스
소개	° 구축목적: 해외 기업 정보에 대한 시장의 수요를 충족하는 서비스를 제공해 가치사슬 전반의 해외 기업 데이터 부족 해소, 다양한 이해관계자의 의사결정 효율화를 도모. ° 데이터 구축 필요성: 벨류체인 확장 및 데이터 중요성을 인지하고 있으나, 데이터 양극화/전문기과 이용의 한계 등에 따라 적극적인 데이터 확보가 어려운 실정. 이러한 한계를 극복하기 위해 해외기업 빅데이터 센터 구축 필요성 대두 ° 활용 분야: 해외기업정보 데이터에 대한 수요는 Supply Chain, Sales 확장, M&A, 투자, 컨설팅 등 산업 전반에 걸쳐 존재 ° 데이터 소개: (국가)기업에 대한 기업 재무정보를 현지 언어와 영문으로 나타냄. - 기업 재무정보: 재무상태표, 포괄손익계산서, 현금흐름표

데이터 설명

데이터 구조: 데이터셋에 따른 항목과 해당 값은 아래와 같습니다(테이블 내 항목 중 일부)

No.	필드명(국문)	필드명(영문)	설명	유형
1	영문기업명	ENGLS_ENTRP_NM	기업의 영어 표기 이름	VARCHAR(100)
2	유동자산금액	CUASS_AMT	재무상태표>자산>유동자산	NUMERIC
3	비유동자산금액	NNCRRNT_ASSTS_AMT	재무상태표>자산>비유동자산	NUMERIC
4	자산총계금액	ASSTS_SUMM	재무상태표>자산>자산총계	NUMERIC
5	유동부채금액	FLTNG_DEBT_AMT	재무상태표>부채>유동부채	NUMERIC
6	비유동부채금액	NNCRRNT_DEBT_AMT	재무상태표>부채>비유동부채	NUMERIC
7	자본금액	CAPTL	재무상태표>자본>자본금	NUMERIC
8	자본총계액	CAPTL_SUMM	재무상태표>자본>자본총계	NUMERIC
9	부채자본총계액	DEBT_CAPTL_SUMM_AMT	재무상태표>자본>부채 및 자본 총계	NUMERIC
10	매출금액	PRSLS	손익계산서>매출액	NUMERIC
11	영업이익금액	BSN_PRFT_AMT	손익계산서>영업이익	NUMERIC
12	당기순이익금액	THTRM_NTPF_AMT	손익계산서>당기순이익>당기순이익(또는 당기순손실)	NUMERIC
13	기초현금금액	BSIS_CASH_AMT	현금흐름표>기초의 현금	NUMERIC
14	기말현금금액	ENTRM_CASH_AMT	현금흐름표>기말의 현금	NUMERIC

데이터 샘플 파일 정보

데이터 샘플 파일 정보
키값	주식시장코드	현지언어주식시장명	영문주식시장명	헤브론스타국가코드	상장코드	현지언어기업명	영문기업명	해외기업법인등록번호	해외기업사업자등록번호	설립일자	상장일자	현지언어산업군명	영문산업군명	통화구분코드	회계연도	보고서종류코드	결산일자	유동자산금액	비유동자산금액	현금및예치금액	유가증권금액	대출채권금액	할부금융자산금액	리스자산금액	유형자산금액	기타자산금액	자산총계	유동부채금액	비유동부채금액	예수부채금액	차입부채금액	기타부채금액	부채총계	자본금	자본잉여금	자본조정금액	기타포괄손익누계액	이익잉여금	자본총계	부채자본총계액	매출액	매출원가금액	영업비용금액	영업이익금액	영업외비용금액	법인세비용차감전순손익금액	법인세비용차감전계속사업손익금액	법인세비용금액	계속사업손익법인세비용금액	계속사업이익금액	중단사업손익금액	당기순이익금액	영업활동현금흐름금액	투자활동현금유입금액	재무활동현금유입금액	현금증가금액	기초현금금액	기말현금금액	부채비율	영업이익율값	매출액증가율	영업이익증가율값	당기순이익증가율값	기업연평균성장률값	기업관련소식날짜	기업관련소식종류내용	기업관련소식제목	기업관련소식내용요약	기업관련소식상세내용	정보출처내용	기업관련소식URL	사내관련정보	고객관련정보	공급관련정보	경쟁관련정보	대체재관련정보
11823	SIX	Swiss Exchange	Swiss Exchange	CHE	HOLN	Holcim Ltd	Holcim Ltd		-		20210818	Building Materials	Building Materials	CHF	2022	Q	20221231	16784000000.0	40819000000.0								57603000000.0	8857000000.0	19132000000.0				27989000000.0						28674000000.0	56663000000.0
1222				CHE	CON									CHF	2020	Q	20201231	813500000	337100000	273300000					255000000	0	1150600000	313800000	40700000			0	354500000				-327100000	812200000	796100000	1150600000
11957	SIX	Swiss Exchange	Swiss Exchange	CHE	NBEN	nebag ag	nebag ag		-		20051104	Asset Management	Asset Management	CHF	2022	Q	20220630	10353842.0	76267276.0								86880901.0	0.0	0.0				5417083.0						81463818.0	86880901.0
261	SIX	Swiss Exchange	Swiss Exchange	CHE	ALPN	Alpine Select AG	Alpine Select AG				20110927	Asset Management	Asset Management	CHF	2018	Q	20180131																								-3590750	0	0	0		-4115500		-165500				-3950000	2703750	0	0	-453750	443250	-10500
12075	SIX	Swiss Exchange	Swiss Exchange	CHE	SIGN	SIG Group AG	SIG Group AG		-		20180928	Packaging & Containers	Packaging & Containers	EUR	2022	Q	20220630	1421100000.0	6134100000.0								7555200000.0	1706400000.0	2636900000.0				4343300000.0						3211900000.0	7555200000.0
12176	SIX	Swiss Exchange	Swiss Exchange	CHE	VATN	Valiant Holding AG	Valiant Holding AG		-		20021209	BanksRegional	BanksRegional	CHF	2022	Q	20220930	5474170000.0	2159880000.0								35913409000.0	0.0	0.0				33505252000.0						2408157000.0	35913409000.0	112642000.0	0.0		47452000.0		36855000.0		6396000.0
3077				CHE	NTIV									CHF	2019	Q	20190331																								34951250	34468500	1887500	-3021750		-3056250		-13500				-1905000	-421500	0	0	-1297000	1311750	14750
12220	SIX	Swiss Exchange	Swiss Exchange	CHE	ZUGN	Zug Estates Holding AG	Zug Estates Holding AG		-		20120702	Real EstateDiversified	Real EstateDiversified	CHF	2022	A	20221231	28709000.0	1763365000.0								1792074000.0	186682000.0	616139000.0				802821000.0						989253000.0	1792074000.0	79807000.0	9954000.0		52978000.0		45219000.0		5419000.0					39397000.0	-105504000.0	64735000.0		18691000.0	17319000.0
12221	SIX	Swiss Exchange	Swiss Exchange	CHE	ZUGN	Zug Estates Holding AG	Zug Estates Holding AG		-		20120702	Real EstateDiversified	Real EstateDiversified	CHF	2022	Q	20221231	28709000.0	1763365000.0								1792074000.0	186682000.0	616139000.0				802821000.0						989253000.0	1792074000.0
12222	SIX	Swiss Exchange	Swiss Exchange	CHE	ZUGN	Zug Estates Holding AG	Zug Estates Holding AG		-		20120702	Real EstateDiversified	Real EstateDiversified	CHF	2022	Q	20220630	21188000.0	1646511000.0								1667699000.0	43014000.0	647332000.0				690346000.0						977353000.0	1667699000.0
12223	SIX	Swiss Exchange	Swiss Exchange	CHE	ZURN	Zurich Insurance Group AG	Zurich Insurance Group AG		-		20001017	InsuranceDiversified	InsuranceDiversified	USD	2022	A	20221231	0.0	0.0								377782000000.0	0.0	0.0				349869000000.0						26634000000.0	376503000000.0	42066000000.0	0.0		0.0		5962000000.0		1040000000.0					5079000000.0	-691000000.0	-5273000000.0		9330000000.0	8155000000.0
10142	SIX	Swiss Exchange	Swiss Exchange	CHE	ZURN	Zurich Insurance Group AG	Zurich Insurance Group AG				20001017	InsuranceDiversified	InsuranceDiversified	USD	2021	Q	20210630																																																20221205	Stock News	Credit Suisse business stable chairman tells broadcaster SRF		Reuters. Axel Lehmann chairman of Swiss bank Credit Suisse poses for a portrait at the lender's office in Singapore August 30 2022. REUTERS/Anshuman Daga/File Photo▦ZURICH (Reuters) -Credit Suisse is definitely stable Chairman Axel Lehmann told Swiss broadcaster SRF on Monday adding that the embattled bank had seen a stabilisation in the outflows of client funds.▦The bank has reported sharp outflows as wealthy clients move assets elsewhere while the bank battles to recover from a string of scandals by focusing more on its flagship wealth management franchise and pruning back investment banking.▦Thankfully the outflows have stabilised Lehman told SRF in an interview to be broadcast on Monday.▦Funds were also starting to return to the bank he said particularly in its Swiss home market.▦Credit Suisse whose shares recently plunged to a record lows is in the midst of an overhaul which has included raising 4 billion Swiss francs ($4.23 billion) to bolster its finances.▦When you have a capital raising which has a big dilution effect that creates a lot of uncertainty and that leads to high volatility Lehmann said in the interview.▦But I believe the situation has calmed. The business is definitely stable he said.▦Still he expected 2023 and 2024 to be years of transformation for the bank as it seeks to stabilise after years of mishaps.▦It's true the whole group will not be profitable next year Lehmann said. What is important is the progress we make.▦What is the earnings power of the Swiss business wealth management asset management and the part of the investment bank we retain and then from 2024 produce positive numbers.	Reuters. Axel Lehmann chairman of Swiss bank Credit Suisse poses for a portrait at the lender's office in Singapore August 30 2022. REUTERS/Anshuman Daga/File Photo▦ZURICH (Reuters) -Credit Suisse is definitely stable Chairman Axel Lehmann told Swiss broadcaster SRF on Monday adding that the embattled bank had seen a stabilisation in the outflows of client funds.▦The bank has reported sharp outflows as wealthy clients move assets elsewhere while the bank battles to recover from a string of scandals by focusing more on its flagship wealth management franchise and pruning back investment banking.▦Thankfully the outflows have stabilised Lehman told SRF in an interview to be broadcast on Monday.▦Funds were also starting to return to the bank he said particularly in its Swiss home market.▦Credit Suisse whose shares recently plunged to a record lows is in the midst of an overhaul which has included raising 4 billion Swiss francs ($4.23 billion) to bolster its finances.▦When you have a capital raising which has a big dilution effect that creates a lot of uncertainty and that leads to high volatility Lehmann said in the interview.▦But I believe the situation has calmed. The business is definitely stable he said.▦Still he expected 2023 and 2024 to be years of transformation for the bank as it seeks to stabilise after years of mishaps.▦It's true the whole group will not be profitable next year Lehmann said. What is important is the progress we make.▦What is the earnings power of the Swiss business wealth management asset management and the part of the investment bank we retain and then from 2024 produce positive numbers.	https://www.investing.com/news/stock-market-news/credit-suisse-business-stable-chairman-tells-broadcaster-srf-2957668	Reuters. Axel Lehmann chairman of Swiss bank Credit Suisse poses for a portrait at the lender's office in Singapore August 30 2022. REUTERS/Anshuman Daga/File Photo▦ZURICH (Reuters) -Credit Suisse is definitely stable Chairman Axel Lehmann told Swiss broadcaster SRF on Monday adding that the embattled bank had seen a stabilisation in the outflows of client funds.▦The bank has reported sharp outflows as wealthy clients move assets elsewhere while the bank battles to recover from a string of scandals by focusing more on its flagship wealth management franchise and pruning back investment banking.▦Thankfully the outflows have stabilised Lehman told SRF in an interview to be broadcast on Monday.▦Funds were also starting to return to the bank he said particularly in its Swiss home market.▦Credit Suisse whose shares recently plunged to a record lows is in the midst of an overhaul which has included raising 4 billion Swiss francs ($4.23 billion) to bolster its finances.▦When you have a capital raising which has a big dilution effect that creates a lot of uncertainty and that leads to high volatility Lehmann said in the interview.▦But I believe the situation has calmed. The business is definitely stable he said.▦Still he expected 2023 and 2024 to be years of transformation for the bank as it seeks to stabilise after years of mishaps.▦It's true the whole group will not be profitable next year Lehmann said. What is important is the progress we make.▦What is the earnings power of the Swiss business wealth management asset management and the part of the investment bank we retain and then from 2024 produce positive numbers.	Reuters. Axel Lehmann chairman of Swiss bank Credit Suisse poses for a portrait at the lender's office in Singapore August 30 2022. REUTERS/Anshuman Daga/File Photo▦ZURICH (Reuters) -Credit Suisse is definitely stable Chairman Axel Lehmann told Swiss broadcaster SRF on Monday adding that the embattled bank had seen a stabilisation in the outflows of client funds.▦The bank has reported sharp outflows as wealthy clients move assets elsewhere while the bank battles to recover from a string of scandals by focusing more on its flagship wealth management franchise and pruning back investment banking.▦Thankfully the outflows have stabilised Lehman told SRF in an interview to be broadcast on Monday.▦Funds were also starting to return to the bank he said particularly in its Swiss home market.▦Credit Suisse whose shares recently plunged to a record lows is in the midst of an overhaul which has included raising 4 billion Swiss francs ($4.23 billion) to bolster its finances.▦When you have a capital raising which has a big dilution effect that creates a lot of uncertainty and that leads to high volatility Lehmann said in the interview.▦But I believe the situation has calmed. The business is definitely stable he said.▦Still he expected 2023 and 2024 to be years of transformation for the bank as it seeks to stabilise after years of mishaps.▦It's true the whole group will not be profitable next year Lehmann said. What is important is the progress we make.▦What is the earnings power of the Swiss business wealth management asset management and the part of the investment bank we retain and then from 2024 produce positive numbers.	Reuters. Axel Lehmann chairman of Swiss bank Credit Suisse poses for a portrait at the lender's office in Singapore August 30 2022. REUTERS/Anshuman Daga/File Photo▦ZURICH (Reuters) -Credit Suisse is definitely stable Chairman Axel Lehmann told Swiss broadcaster SRF on Monday adding that the embattled bank had seen a stabilisation in the outflows of client funds.▦The bank has reported sharp outflows as wealthy clients move assets elsewhere while the bank battles to recover from a string of scandals by focusing more on its flagship wealth management franchise and pruning back investment banking.▦Thankfully the outflows have stabilised Lehman told SRF in an interview to be broadcast on Monday.▦Funds were also starting to return to the bank he said particularly in its Swiss home market.▦Credit Suisse whose shares recently plunged to a record lows is in the midst of an overhaul which has included raising 4 billion Swiss francs ($4.23 billion) to bolster its finances.▦When you have a capital raising which has a big dilution effect that creates a lot of uncertainty and that leads to high volatility Lehmann said in the interview.▦But I believe the situation has calmed. The business is definitely stable he said.▦Still he expected 2023 and 2024 to be years of transformation for the bank as it seeks to stabilise after years of mishaps.▦It's true the whole group will not be profitable next year Lehmann said. What is important is the progress we make.▦What is the earnings power of the Swiss business wealth management asset management and the part of the investment bank we retain and then from 2024 produce positive numbers.	Reuters. Axel Lehmann chairman of Swiss bank Credit Suisse poses for a portrait at the lender's office in Singapore August 30 2022. REUTERS/Anshuman Daga/File Photo▦ZURICH (Reuters) -Credit Suisse is definitely stable Chairman Axel Lehmann told Swiss broadcaster SRF on Monday adding that the embattled bank had seen a stabilisation in the outflows of client funds.▦The bank has reported sharp outflows as wealthy clients move assets elsewhere while the bank battles to recover from a string of scandals by focusing more on its flagship wealth management franchise and pruning back investment banking.▦Thankfully the outflows have stabilised Lehman told SRF in an interview to be broadcast on Monday.▦Funds were also starting to return to the bank he said particularly in its Swiss home market.▦Credit Suisse whose shares recently plunged to a record lows is in the midst of an overhaul which has included raising 4 billion Swiss francs ($4.23 billion) to bolster its finances.▦When you have a capital raising which has a big dilution effect that creates a lot of uncertainty and that leads to high volatility Lehmann said in the interview.▦But I believe the situation has calmed. The business is definitely stable he said.▦Still he expected 2023 and 2024 to be years of transformation for the bank as it seeks to stabilise after years of mishaps.▦It's true the whole group will not be profitable next year Lehmann said. What is important is the progress we make.▦What is the earnings power of the Swiss business wealth management asset management and the part of the investment bank we retain and then from 2024 produce positive numbers.	Reuters. Axel Lehmann chairman of Swiss bank Credit Suisse poses for a portrait at the lender's office in Singapore August 30 2022. REUTERS/Anshuman Daga/File Photo▦ZURICH (Reuters) -Credit Suisse is definitely stable Chairman Axel Lehmann told Swiss broadcaster SRF on Monday adding that the embattled bank had seen a stabilisation in the outflows of client funds.▦The bank has reported sharp outflows as wealthy clients move assets elsewhere while the bank battles to recover from a string of scandals by focusing more on its flagship wealth management franchise and pruning back investment banking.▦Thankfully the outflows have stabilised Lehman told SRF in an interview to be broadcast on Monday.▦Funds were also starting to return to the bank he
12224	SIX	Swiss Exchange	Swiss Exchange	CHE	ZURN	Zurich Insurance Group AG	Zurich Insurance Group AG		-		20001017	InsuranceDiversified	InsuranceDiversified	USD	2022	Q	20221231	0.0	0.0								377782000000.0	0.0	0.0				349869000000.0						26634000000.0	376503000000.0
12225	SIX	Swiss Exchange	Swiss Exchange	CHE	ZURN	Zurich Insurance Group AG	Zurich Insurance Group AG		-		20001017	InsuranceDiversified	InsuranceDiversified	USD	2022	Q	20220630	0.0	0.0								386409000000.0	0.0	0.0				357368000000.0						27780000000.0	385148000000.0
7985	SIX	Swiss Exchange	Swiss Exchange	CHE	MOLN	Molecular Partners AG	Molecular Partners AG				20141022	Biotechnology	Biotechnology	CHF	2021	Q	20210930																																																20221205	Stock News			Reuters. Master of ceremonies Galbraith presents the Worst of Show to a 1964 Ford Fairline at the Concours d'Lemon part of the Pebble Beach Concours d'Elegance in Seaside▦ CSGN▦-5.41%▦By Paul Ingrassia▦MONTEREY Calif. (Reuters) - When it began 65 years ago the Pebble Beach Concours d'Elegance was just a one-day affair. Car enthusiasts raced around Pebble Beach's famed 17-Mile Drive and hung around afterwards to admire each other's hardware.▦Now the day has become a week. It includes road rallies races auctions displays seminars exhibitions parties and underpinning it all marketing. Lamborghini unveiled its newest model - the 700-horsepower $400000 Aventador - here Friday. Lalique the crystal maker Wednesday released a book about its history of car mascots aka hood ornaments.▦Tesla has a display tent. Rolex Credit Suisse (SIX:CSGN) and others sponsor events. Korea's Kia hopes to creep into the luxury market by offering test drives of its K900 sedan which is priced at $54000 and up.▦The week's events are spread throughout the Monterey region from the tony-rustic Carmel Valley to the gritty working-class town of Seaside home to Saturday's tongue-in-cheek Concours d'Lemons. It's a deliberately downscale celebration of Edsels Gremlins Corvairs and Yugos - some of history's worst cars.▦Sunday's Concours d'Elegance on the 18th fairway of the Pebble Beach golf course is focused instead on finery with Ferraris Bugattis Hispano-Suizas and other rarified cars competing for Best-in-Show honors. Expected attendance for the day is up to 25000 at the show itself and more at side events.▦Hard-core enthusiasts arrive for the 6 a.m. Dawn Patrol to watch the 200-or-so cars on display all by invitation only roll onto the 18th fairway while the morning mist rolls in from the adjacent Monterey Bay. This year's featured categories and classes include Ferrari pre-war British sports cars and the Lincoln Continental on its 75th anniversary year.▦It's the Super Bowl of car shows says Dave Magers CEO of Mecum Auctions which this weekend sold a Porsche once owned by the late actor Steve McQueen for $1.95 million. At the swank Bonhams auction at Carmel Valley's Quail Lodge some cars could fetch more than 10 times that price. All told collectors are expected to spend more than $400 million on cars sold at auction during the week.▦The week of excess everything includes epic traffic jams that can stretch for miles along California Highway 1. As a resident we hate it says retiree Marty Goss a long-time Carmel resident. It's a huge influx of traffic and people. But it is great for the local economy.▦Indeed the local convention bureau expects more than 85000 visitors will drop more than $50 million on hotel rooms restaurants and bar tabs. Concours proceeds go to local charities.▦The number of Car Week events has proliferated such that Sports Car Market a collectors magazine publishes a special Monterey issue that offers attendees blunt advice. Get up early to avoid traffic the magazine states and carefully pick your events to avoid epic burnout.▦--------------▦Paul Ingrassia managing editor of Reuters has written three automotive books and is an honorary judge at the Pebble Beach Concours d'Elegance.	Reuters. Master of ceremonies Galbraith presents the Worst of Show to a 1964 Ford Fairline at the Concours d'Lemon part of the Pebble Beach Concours d'Elegance in Seaside▦ CSGN▦-5.41%▦By Paul Ingrassia▦MONTEREY Calif. (Reuters) - When it began 65 years ago the Pebble Beach Concours d'Elegance was just a one-day affair. Car enthusiasts raced around Pebble Beach's famed 17-Mile Drive and hung around afterwards to admire each other's hardware.▦Now the day has become a week. It includes road rallies races auctions displays seminars exhibitions parties and underpinning it all marketing. Lamborghini unveiled its newest model - the 700-horsepower $400000 Aventador - here Friday. Lalique the crystal maker Wednesday released a book about its history of car mascots aka hood ornaments.▦Tesla has a display tent. Rolex Credit Suisse (SIX:CSGN) and others sponsor events. Korea's Kia hopes to creep into the luxury market by offering test drives of its K900 sedan which is priced at $54000 and up.▦The week's events are spread throughout the Monterey region from the tony-rustic Carmel Valley to the gritty working-class town of Seaside home to Saturday's tongue-in-cheek Concours d'Lemons. It's a deliberately downscale celebration of Edsels Gremlins Corvairs and Yugos - some of history's worst cars.▦Sunday's Concours d'Elegance on the 18th fairway of the Pebble Beach golf course is focused instead on finery with Ferraris Bugattis Hispano-Suizas and other rarified cars competing for Best-in-Show honors. Expected attendance for the day is up to 25000 at the show itself and more at side events.▦Hard-core enthusiasts arrive for the 6 a.m. Dawn Patrol to watch the 200-or-so cars on display all by invitation only roll onto the 18th fairway while the morning mist rolls in from the adjacent Monterey Bay. This year's featured categories and classes include Ferrari pre-war British sports cars and the Lincoln Continental on its 75th anniversary year.▦It's the Super Bowl of car shows says Dave Magers CEO of Mecum Auctions which this weekend sold a Porsche once owned by the late actor Steve McQueen for $1.95 million. At the swank Bonhams auction at Carmel Valley's Quail Lodge some cars could fetch more than 10 times that price. All told collectors are expected to spend more than $400 million on cars sold at auction during the week.▦The week of excess everything includes epic traffic jams that can stretch for miles along California Highway 1. As a resident we hate it says retiree Marty Goss a long-time Carmel resident. It's a huge influx of traffic and people. But it is great for the local economy.▦Indeed the local convention bureau expects more than 85000 visitors will drop more than $50 million on hotel rooms restaurants and bar tabs. Concours proceeds go to local charities.▦The number of Car Week events has proliferated such that Sports Car Market a collectors magazine publishes a special Monterey issue that offers attendees blunt advice. Get up early to avoid traffic the magazine states and carefully pick your events to avoid epic burnout.▦--------------▦Paul Ingrassia managing editor of Reuters has written three automotive books and is an honorary judge at the Pebble Beach Concours d'Elegance.	https://www.investing.com/news/general-news/cars-on-fairway:-pebble-beach-concours-culminates-auto-mania-week-356158	Reuters. Master of ceremonies Galbraith presents the Worst of Show to a 1964 Ford Fairline at the Concours d'Lemon part of the Pebble Beach Concours d'Elegance in Seaside▦ CSGN▦-5.41%▦By Paul Ingrassia▦MONTEREY Calif. (Reuters) - When it began 65 years ago the Pebble Beach Concours d'Elegance was just a one-day affair. Car enthusiasts raced around Pebble Beach's famed 17-Mile Drive and hung around afterwards to admire each other's hardware.▦Now the day has become a week. It includes road rallies races auctions displays seminars exhibitions parties and underpinning it all marketing. Lamborghini unveiled its newest model - the 700-horsepower $400000 Aventador - here Friday. Lalique the crystal maker Wednesday released a book about its history of car mascots aka hood ornaments.▦Tesla has a display tent. Rolex Credit Suisse (SIX:CSGN) and others sponsor events. Korea's Kia hopes to creep into the luxury market by offering test drives of its K900 sedan which is priced at $54000 and up.▦The week's events are spread throughout the Monterey region from the tony-rustic Carmel Valley to the gritty working-class town of Seaside home to Saturday's tongue-in-cheek Concours d'Lemons. It's a deliberately downscale celebration of Edsels Gremlins Corvairs and Yugos - some of history's worst cars.▦Sunday's Concours d'Elegance on the 18th fairway of the Pebble Beach golf course is focused instead on finery with Ferraris Bugattis Hispano-Suizas and other rarified cars competing for Best-in-Show honors. Expected attendance for the day is up to 25000 at the show itself and more at side events.▦Hard-core enthusiasts arrive for the 6 a.m. Dawn Patrol to watch the 200-or-so cars on display all by invitation only roll onto the 18th fairway while the morning mist rolls in from the adjacent Monterey Bay. This year's featured categories and classes include Ferrari pre-war British sports cars and the Lincoln Continental on its 75th anniversary year.▦It's the Super Bowl of car shows says Dave Magers CEO of Mecum Auctions which this weekend sold a Porsche once owned by the late actor Steve McQueen for $1.95 million. At the swank Bonhams auction at Carmel Valley's Quail Lodge some cars could fetch more than 10 times that price. All told collectors are expected to spend more than $400 million on cars sold at auction during the week.▦The week of excess everything includes epic traffic jams that can stretch for miles along California Highway 1. As a resident we hate it says retiree Marty Goss a long-time Carmel resident. It's a huge influx of traffic and people. But it is great for the local economy.▦Indeed the local convention bureau expects more than 85000 visitors will drop more than $50 million on hotel rooms restaurants and bar tabs. Concours proceeds go to local charities.▦The number of Car Week events has proliferated such that Sports Car Market a collectors magazine publishes a special Monterey issue that offers attendees blunt advice. Get up early to avoid traffic the magazine states and carefully pick your events to avoid epic burnout.▦--------------▦Paul Ingrassia managing editor of Reuters has written three automotive books and is an honorary judge at the Pebble Beach Concours d'Elegance.	Reuters. Master of ceremonies Galbraith presents the Worst of Show to a 1964 Ford Fairline at the Concours d'Lemon part of the Pebble Beach Concours d'Elegance in Seaside▦ CSGN▦-5.41%▦By Paul Ingrassia▦MONTEREY Calif. (Reuters) - When it began 65 years ago the Pebble Beach Concours d'Elegance was just a one-day affair. Car enthusiasts raced around Pebble Beach's famed 17-Mile Drive and hung around afterwards to admire each other's hardware.▦Now the day has become a week. It includes road rallies races auctions displays seminars exhibitions parties and underpinning it all marketing. Lamborghini unveiled its newest model - the 700-horsepower $400000 Aventador - here Friday. Lalique the crystal maker Wednesday released a book about its history of car mascots aka hood ornaments.▦Tesla has a display tent. Rolex Credit Suisse (SIX:CSGN) and others sponsor events. Korea's Kia hopes to creep into the luxury market by offering test drives of its K900 sedan which is priced at $54000 and up.▦The week's events are spread throughout the Monterey region from the tony-rustic Carmel Valley to the gritty working-class town of Seaside home to Saturday's tongue-in-cheek Concours d'Lemons. It's a deliberately downscale celebration of Edsels Gremlins Corvairs and Yugos - some of history's worst cars.▦Sunday's Concours d'Elegance on the 18th fairway of the Pebble Beach golf course is focused instead on finery with Ferraris Bugattis Hispano-Suizas and other rarified cars competing for Best-in-Show honors. Expected attendance for the day is up to 25000 at the show itself and more at side events.▦Hard-core enthusiasts arrive for the 6 a.m. Dawn Patrol to watch the 200-or-so cars on display all by invitation only roll onto the 18th fairway while the morning mist rolls in from the adjacent Monterey Bay. This year's featured categories and classes include Ferrari pre-war British sports cars and the Lincoln Continental on its 75th anniversary year.▦It's the Super Bowl of car shows says Dave Magers CEO of Mecum Auctions which this weekend sold a Porsche once owned by the late actor Steve McQueen for $1.95 million. At the swank Bonhams auction at Carmel Valley's Quail Lodge some cars could fetch more than 10 times that price. All told collectors are expected to spend more than $400 million on cars sold at auction during the week.▦The week of excess everything includes epic traffic jams that can stretch for miles along California Highway 1. As a resident we hate it says retiree Marty Goss a long-time Carmel resident. It's a huge influx of traffic and people. But it is great for the local economy.▦Indeed the local convention bureau expects more than 85000 visitors will drop more than $50 million on hotel rooms restaurants and bar tabs. Concours proceeds go to local charities.▦The number of Car Week events has proliferated such that Sports Car Market a collectors magazine publishes a special Monterey issue that offers attendees blunt advice. Get up early to avoid traffic the magazine states and carefully pick your events to avoid epic burnout.▦--------------▦Paul Ingrassia managing editor of Reuters has written three automotive books and is an honorary judge at the Pebble Beach Concours d'Elegance.	Reuters. Master of ceremonies Galbraith presents the Worst of Show to a 1964 Ford Fairline at the Concours d'Lemon part of the Pebble Beach Concours d'Elegance in Seaside▦ CSGN▦-5.41%▦By Paul Ingrassia▦MONTEREY Calif. (Reuters) - When it began 65 years ago the Pebble Beach Concours d'Elegance was just a one-day affair. Car enthusiasts raced around Pebble Beach's famed 17-Mile Drive and hung around afterwards to admire each other's hardware.▦Now the day has become a week. It includes road rallies races auctions displays seminars exhibitions parties and underpinning it all marketing. Lamborghini unveiled its newest model - the 700-horsepower $400000 Aventador - here Friday. Lalique the crystal maker Wednesday released a book about its history of car mascots aka hood ornaments.▦Tesla has a display tent. Rolex Credit Suisse (SIX:CSGN) and others sponsor events. Korea's Kia hopes to creep into the luxury market by offering test drives of its K900 sedan which is priced at $54000 and up.▦The week's events are spread throughout the Monterey region from the tony-rustic Carmel Valley to the gritty working-class town of Seaside home to Saturday's tongue-in-cheek Concours d'Lemons. It's a deliberately downscale celebration of Edsels Gremlins Corvairs and Yugos - some of history's worst cars.▦Sunday's Concours d'Elegance on the 18th fairway of the Pebble Beach golf course is focused instead on finery with Ferraris Bugattis Hispano-Suizas and other rarified cars competing for Best-in-Show honors. Expected attendance for the day is up to 25000 at the show itself and more at side events.▦Hard-core enthusiasts arrive for the 6 a.m. Dawn Patrol to watch the 200-or-so cars on display all by invitation only roll onto the 18th fairway while the morning mist rolls in from the adjacent Monterey Bay. This year's featured categories and classes include Ferrari pre-war British sports cars and the Lincoln Continental on its 75th anniversary year.▦It's the Super Bowl of car shows says Dave Magers CEO of Mecum Auctions which this weekend sold a Porsche once owned by the late actor Steve McQueen for $1.95 million. At the swank Bonhams auction at Carmel Valley's Quail Lodge some cars could fetch more than 10 times that price. All told collectors are expected to spend more than $400 million on cars sold at auction during the week.▦The week of excess everything includes epic traffic jams that can stretch for miles along California Highway 1. As a resident we hate it says retiree Marty Goss a long-time Carmel resident. It's a huge influx of traffic and people. But it is great for the local economy.▦Indeed the local convention bureau expects more than 85000 visitors will drop more than $50 million on hotel rooms restaurants and bar tabs. Concours proceeds go to local charities.▦The number of Car Week events has proliferated such that Sports Car Market a collectors magazine publishes a special Monterey issue that offers attendees blunt advice. Get up early to avoid traffic the magazine states and carefully pick your events to avoid epic burnout.▦--------------▦Paul Ingrassia managing editor of Reuters has written three automotive books and is an honorary judge at the Pebble Beach Concours d'Elegance.	Reuters. Master of ceremonies Galbraith presents the Worst of Show to a 1964 Ford Fairline at the Concours d'Lemon part of the Pebble Beach Concours d'Elegance in Seaside▦ CSGN▦-5.41%▦By Paul Ingrassia▦MONTEREY Calif. (Reuters) - When it began 65 years ago the Pebble Beach Concours d'Elegance was just a one-day affair. Car enthusiasts raced around Pebble Beach's famed 17-Mile Drive and hung around afterwards to admire each other's hardware.▦Now the day has become a week. It includes road rallies races auctions displays seminars exhibitions parties and underpinning it all marketing. Lamborghini unveiled its newest model - the 700-horsepower $400000 Aventador - here Friday. Lalique the crystal maker Wednesday released a book about its history of car mascots aka hood ornaments.▦Tesla has a display tent. Rolex Credit Suisse (SIX:CSGN) and others sponsor events. Korea's Kia hopes to creep into the luxury market by offering test drives of its K900 sedan which is priced at $54000 and up.▦The week's events are spread throughout the Monterey region from the tony-rustic Carmel Valley to the gritty working-class town of Seaside home to Saturday's tongue-in-cheek Concours d'Lemons. It's a deliberately downscale celebration of Edsels Gremlins Corvairs and Yugos - some of history's worst cars.▦Sunday's Concours d'Elegance on the 18th fairway of the Pebble Beach golf course is focused instead on finery with Ferraris Bugattis Hispano-Suizas and other rarified cars competing for Best-in-Show honors. Expected attendance for the day is up to 25000 at the show itself and more at side events.▦Hard-core enthusiasts arrive for the 6 a.m. Dawn Patrol to watch the 200-or-so cars on display all by invitation only roll onto the 18th fairway while the morning mist rolls in from the adjacent Monterey Bay. This year's featured categories and classes include Ferrari pre-war British sports cars and the Lincoln Continental on its 75th anniversary year.▦It's the Super Bowl of car shows says Dave Magers CEO of Mecum Auctions which this weekend sold a Porsche once owned by the late actor Steve McQueen for $1.95 million. At the swank Bonhams auction at Carmel Valley's Quail Lodge some cars could fetch more than 10 times that price. All told collectors are expected to spend more than $400 million on cars sold at auction during the week.▦The week of excess everything includes epic traffic jams that can stretch for miles along California Highway 1. As a resident we hate it says retiree Marty Goss a long-time Carmel resident. It's a huge influx of traffic and people. But it is great for the local economy.▦Indeed the local convention bureau expects more than 85000 visitors will drop more than $50 million on hotel rooms restaurants and bar tabs. Concours proceeds go to local charities.▦The number of Car Week events has proliferated such that Sports Car Market a collectors magazine publishes a special Monterey issue that offers attendees blunt advice. Get up early to avoid traffic the magazine states and carefully pick your events to avoid epic burnout.▦--------------▦Paul Ingrassia managing editor of Reuters has written three automotive books and is an honorary judge at the Pebble Beach Concours d'Elegance.	Reuters. Master of ceremonies Galbraith presents the Worst of Show to a 1964 Ford Fairline at the Concours d'Lemon part of the Pebble Beach Concours d'Elegance in Seaside▦ CSGN▦-5.41%▦By Paul Ingrassia▦MONTEREY Calif. (Reuters) - When it began 65 years ago the Pebble Beach Concours d'Elegance was just a one-day affair. Car enthusiasts raced around Pebble Beach's famed 17-Mile Drive and hung around afterwards to admire each other's hardware.▦Now the day has become a week. It includes road rallies races auctions displays seminars exhibitions parties and underpinning it all marketing. Lamborghini unveiled its newest model - the 700-horsepower $400000 Aventador - here Friday. Lalique the crystal maker Wednesday released a book about its histor
11557	SIX	Swiss Exchange	Swiss Exchange	CHE	AAM	Anglo American plc	Anglo American plc		-		19990524	Other Industrial Metals & Mining	Other Industrial Metals & Mining	USD	2022	A	20221231	19936000000.0	47471000000.0								67407000000.0	10494000000.0	22889000000.0				33383000000.0						27361000000.0	67407000000.0	35118000000.0	15526000000.0		9243000000.0		9480000000.0		3456000000.0					9765000000.0	-5817000000.0	-4368000000.0		9057000000.0	8400000000.0
11558	SIX	Swiss Exchange	Swiss Exchange	CHE	AAM	Anglo American plc	Anglo American plc		-		19990524	Other Industrial Metals & Mining	Other Industrial Metals & Mining	USD	2022	Q	20221231	19936000000.0	47471000000.0								67407000000.0	10494000000.0	22889000000.0				33383000000.0						27361000000.0	67407000000.0
11559	SIX	Swiss Exchange	Swiss Exchange	CHE	AAM	Anglo American plc	Anglo American plc		-		19990524	Other Industrial Metals & Mining	Other Industrial Metals & Mining	USD	2022	Q	20220630	19495000000.0	47166000000.0								66661000000.0	10277000000.0	20873000000.0				31150000000.0						28578000000.0	66661000000.0
11560	SIX	Swiss Exchange	Swiss Exchange	CHE	ABBN	ABB Ltd	ABB Ltd		-		20010507	Electrical Equipment & Parts	Electrical Equipment & Parts	USD	2022	A	20221231	19570000000.0	19578000000.0								39148000000.0	16529000000.0	9347000000.0				25876000000.0						12777000000.0	38653000000.0	29446000000.0	19736000000.0		3337000000.0		3394000000.0		757000000.0					1287000000.0	981000000.0	-2394000000.0		4489000000.0	4174000000.0
11561	SIX	Swiss Exchange	Swiss Exchange	CHE	ABBN	ABB Ltd	ABB Ltd		-		20010507	Electrical Equipment & Parts	Electrical Equipment & Parts	USD	2022	Q	20221231	19570000000.0	19578000000.0								39148000000.0	16529000000.0	9347000000.0				25876000000.0						12777000000.0	38653000000.0	7824000000.0	5166000000.0		1185000000.0		1197000000.0		29000000.0					687000000.0	1494000000.0	-697000000.0		2688000000.0	4174000000.0
11562	SIX	Swiss Exchange	Swiss Exchange	CHE	ABBN	ABB Ltd	ABB Ltd		-		20010507	Electrical Equipment & Parts	Electrical Equipment & Parts	USD	2022	Q	20220930	17862000000.0	20571000000.0								38433000000.0	17094000000.0	9096000000.0				26190000000.0						11822000000.0	38012000000.0	7406000000.0	4925000000.0		708000000.0		714000000.0		294000000.0					791000000.0	-256000000.0	-468000000.0		2736000000.0	2688000000.0
11563	SIX	Swiss Exchange	Swiss Exchange	CHE	ABBN	ABB Ltd	ABB Ltd		-		20010507	Electrical Equipment & Parts	Electrical Equipment & Parts	USD	2022	Q	20220630	17758000000.0	21140000000.0								38898000000.0	16697000000.0	9535000000.0				26232000000.0						12271000000.0	38503000000.0	7251000000.0	4961000000.0		587000000.0		599000000.0		193000000.0					382000000.0	-192000000.0	-2920000000.0		5546000000.0	2736000000.0
11564	SIX	Swiss Exchange	Swiss Exchange	CHE	ABBN	ABB Ltd	ABB Ltd		-		20010507	Electrical Equipment & Parts	Electrical Equipment & Parts	USD	2022	Q	20220331	20474000000.0	21797000000.0								42271000000.0	17855000000.0	10698000000.0				28553000000.0						13247000000.0	41800000000.0	6965000000.0	4684000000.0		857000000.0		884000000.0		241000000.0					-573000000.0	-65000000.0	1691000000.0		4489000000.0	5546000000.0
11565	SIX	Swiss Exchange	Swiss Exchange	CHE	ADEN	Adecco Group AG	Adecco Group AG		-		20010514	Staffing & Employment Services	Staffing & Employment Services	EUR	2022	A	20221231	6124000000.0	7132000000.0								13256000000.0	5198000000.0	4165000000.0				9363000000.0						3881000000.0	13244000000.0	23640000000.0	18666000000.0		547000000.0		451000000.0		106000000.0					543000000.0	-1446000000.0	-1383000000.0		3155000000.0	909000000.0
11566	SIX	Swiss Exchange	Swiss Exchange	CHE	ADEN	Adecco Group AG	Adecco Group AG		-		20010514	Staffing & Employment Services	Staffing & Employment Services	EUR	2022	Q	20221231	6124000000.0	7132000000.0								13256000000.0	5198000000.0	4165000000.0				9363000000.0						3881000000.0	13244000000.0	6212000000.0	4910000000.0		113000000.0		77000000.0		12000000.0					459000000.0	-90000000.0	71000000.0		537000000.0	909000000.0
11567	SIX	Swiss Exchange	Swiss Exchange	CHE	ADEN	Adecco Group AG	Adecco Group AG		-		20010514	Staffing & Employment Services	Staffing & Employment Services	EUR	2022	Q	20220930	5936000000.0	7290000000.0								13226000000.0	5395000000.0	3837000000.0				9232000000.0						3981000000.0	13213000000.0	6044000000.0	4777000000.0		164000000.0		145000000.0		35000000.0					110000000.0	-85000000.0	-97000000.0		556000000.0	537000000.0
11568	SIX	Swiss Exchange	Swiss Exchange	CHE	ADEN	Adecco Group AG	Adecco Group AG		-		20010514	Staffing & Employment Services	Staffing & Employment Services	EUR	2022	Q	20220630	5851000000.0	7145000000.0								12996000000.0	5422000000.0	3798000000.0				9220000000.0						3764000000.0	12984000000.0	5938000000.0	4684000000.0		124000000.0		101000000.0		25000000.0					-81000000.0	-494000000.0	-773000000.0		1879000000.0	556000000.0
11569	SIX	Swiss Exchange	Swiss Exchange	CHE	ADEN	Adecco Group AG	Adecco Group AG		-		20010514	Staffing & Employment Services	Staffing & Employment Services	EUR	2022	Q	20220331	6947000000.0	6734000000.0								13681000000.0	5305000000.0	3799000000.0				9104000000.0						4026000000.0	13130000000.0	5446000000.0	4295000000.0		146000000.0		128000000.0		34000000.0					55000000.0	-777000000.0	-584000000.0		3155000000.0	1879000000.0
11570	SIX	Swiss Exchange	Swiss Exchange	CHE	ADVN	Adval Tech Holding AG	Adval Tech Holding AG		-		19980604	Metal Fabrication	Metal Fabrication	CHF	2022	A	20221231	109939000.0	55695000.0								165634000.0	40459000.0	3798000.0				44257000.0						121377000.0	165634000.0	178365000.0	101849000.0		-912000.0		-532000.0		1816000.0					1563000.0	-3022000.0	-1804000.0		31946000.0	28601000.0
11571	SIX	Swiss Exchange	Swiss Exchange	CHE	ADVN	Adval Tech Holding AG	Adval Tech Holding AG		-		19980604	Metal Fabrication	Metal Fabrication	CHF	2022	Q	20221231	109939000.0	55695000.0								165634000.0	40459000.0	3798000.0				44257000.0						121377000.0	165634000.0
11572	SIX	Swiss Exchange	Swiss Exchange	CHE	ADVN	Adval Tech Holding AG	Adval Tech Holding AG		-		19980604	Metal Fabrication	Metal Fabrication	CHF	2022	Q	20220630	105000000.0	58759000.0								163759000.0	34754000.0	4472000.0				39226000.0						124533000.0	163759000.0
11573	SIX	Swiss Exchange	Swiss Exchange	CHE	ADXN	Addex Therapeutics Ltd	Addex Therapeutics Ltd		-		20070522	Biotechnology	Biotechnology	CHF	2022	A	20221231	7828961.0	453089.0								8282050.0	3282111.0	87028.0				3369139.0						4912911.0	8282050.0	1422438.0	0.0		-20520207.0		-20804213.0		264360.0					-16437185.0	2972.0	3102688.0		20484836.0	6957086.0
11574	SIX	Swiss Exchange	Swiss Exchange	CHE	ADXN	Addex Therapeutics Ltd	Addex Therapeutics Ltd		-		20070522	Biotechnology	Biotechnology	CHF	2022	Q	20221231	7828961.0	453089.0								8282050.0	3282111.0	87028.0				3369139.0						4912911.0	8282050.0	592430.0	0.0		-3498440.0		-3651596.0		170736.0					-3071808.0	-9.0	-168900.0		10422835.0	6957086.0
11575	SIX	Swiss Exchange	Swiss Exchange	CHE	ADXN	Addex Therapeutics Ltd	Addex Therapeutics Ltd		-		20070522	Biotechnology	Biotechnology	CHF	2022	Q	20220930	11700615.0	540961.0								12241576.0	4128665.0	161184.0				4289849.0						7951727.0	12241576.0	409417.0	0.0		-4166967.0		-4107630.0		-59337.0					-2690472.0	2981.0	4186194.0		8812858.0	10422835.0
11576	SIX	Swiss Exchange	Swiss Exchange	CHE	ADXN	Addex Therapeutics Ltd	Addex Therapeutics Ltd		-		20070522	Biotechnology	Biotechnology	CHF	2022	Q	20220630	10946136.0	435913.0								11382049.0	4296152.0	223445.0				4519597.0						6862452.0	11382049.0	183354.0	0.0		-7092215.0		-7221252.0		129037.0					-5830281.0	0.0	-170254.0		14887838.0	8812858.0
11577	SIX	Swiss Exchange	Swiss Exchange	CHE	ADXN	Addex Therapeutics Ltd	Addex Therapeutics Ltd		-		20070522	Biotechnology	Biotechnology	CHF	2022	Q	20220331	17162171.0	519134.0								17681305.0	3972471.0	753521.0				4725992.0						12955313.0	17681305.0	237237.0	0.0		-5762585.0		-5823735.0		61150.0					-4844624.0	0.0	-744352.0		20484836.0	14887838.0
11578	SIX	Swiss Exchange	Swiss Exchange	CHE	AERO	Montana Aerospace AG	Montana Aerospace AG		-		20210511	Aerospace & Defense	Aerospace & Defense	EUR	2022	Q	20220930	1097123000.0	1187979000.0								2285102000.0	423982000.0	908164000.0				1332146000.0						954432000.0	2285102000.0	343789000.0	219005000.0		-10230000.0		-23095000.0		5056000.0					-8267000.0	-44190000.0	2073000.0		364529000.0	316798000.0
4453				CHE	TSCO									GBP	2017	Q	20170131																								13979250000	13253750000	58750000	292000000		36250000		21750000				-10000000	497250000	0	0	184750000	770500000	955250000
11579	SIX	Swiss Exchange	Swiss Exchange	CHE	AERO	Montana Aerospace AG	Montana Aerospace AG		-		20210511	Aerospace & Defense	Aerospace & Defense	EUR	2022	Q	20220630	1066067000.0	1144028000.0								2210095000.0	439088000.0	800117000.0				1239205000.0						971993000.0	2210095000.0	335524000.0	205306000.0		-11797000.0		-19093000.0		205000.0					-14741000.0	-16347000.0	2879000.0		390546000.0	364529000.0
11580	SIX	Swiss Exchange	Swiss Exchange	CHE	AERO	Montana Aerospace AG	Montana Aerospace AG		-		20210511	Aerospace & Defense	Aerospace & Defense	EUR	2022	Q	20220331	1034833000.0	1120936000.0								2155769000.0	481618000.0	765635000.0				1247253000.0						909314000.0	2155769000.0	243287000.0	149973000.0		-1374000.0		-6382000.0		805000.0					-37439000.0	-83719000.0	1861000.0		509059000.0	390546000.0
11581	SIX	Swiss Exchange	Swiss Exchange	CHE	AEVS	Aevis Victoria SA	Aevis Victoria SA		-		19990705	Medical Care Facilities	Medical Care Facilities	CHF	2022	A	20221231	380556000.0	1410170000.0								1790726000.0	333716000.0	946873000.0				1280589000.0						469339000.0	1790726000.0	1088013000.0	224869000.0		35636000.0		66513000.0		4679000.0					114300000.0	-56742000.0	-45531000.0		63418000.0	75427000.0
11582	SIX	Swiss Exchange	Swiss Exchange	CHE	AEVS	Aevis Victoria SA	Aevis Victoria SA		-		19990705	Medical Care Facilities	Medical Care Facilities	CHF	2022	Q	20221231	380556000.0	1410170000.0								1790726000.0	333716000.0	946873000.0				1280589000.0						469339000.0	1790726000.0
11583	SIX	Swiss Exchange	Swiss Exchange	CHE	AEVS	Aevis Victoria SA	Aevis Victoria SA		-		19990705	Medical Care Facilities	Medical Care Facilities	CHF	2022	Q	20220630	387414000.0	1446827000.0								1834241000.0	425439000.0	799565000.0				1225004000.0						509042000.0	1834241000.0
11584	SIX	Swiss Exchange	Swiss Exchange	CHE	AFP	Aluflexpack AG	Aluflexpack AG		-		20190628	Packaging & Containers	Packaging & Containers	EUR	2022	A	20221231	175962000.0	272077000.0								448039000.0	130948000.0	124697000.0				255645000.0						190774000.0	448039000.0	357031000.0	240962000.0		8203000.0		6163000.0		1729000.0					14743000.0	-84945000.0	78089000.0		15614000.0	23300000.0
11585	SIX	Swiss Exchange	Swiss Exchange	CHE	AFP	Aluflexpack AG	Aluflexpack AG		-		20190628	Packaging & Containers	Packaging & Containers	EUR	2022	Q	20221231	175962000.0	272077000.0								448039000.0	130948000.0	124697000.0				255645000.0						190774000.0	448039000.0
11586	SIX	Swiss Exchange	Swiss Exchange	CHE	AFP	Aluflexpack AG	Aluflexpack AG		-		20190628	Packaging & Containers	Packaging & Containers	EUR	2022	Q	20220630	161164000.0	241128000.0								402292000.0	87832000.0	125240000.0				213072000.0						187718000.0	402292000.0
11587	SIX	Swiss Exchange	Swiss Exchange	CHE	AIRE	Airesis SA	Airesis SA		-		20000717	Leisure	Leisure	CHF	2022	Q	20220630	86827000.0	62559000.0								149386000.0	95150000.0	63147000.0				158297000.0						-7394000.0	149386000.0
5389	SIX	Swiss Exchange	Swiss Exchange	CHE	AMS	ams-OSRAM AG	ams-OSRAM AG				20040517	Semiconductors	Semiconductors	EUR	2017	Q	20170331																																																20200922	Stock News	Ams and Osram conclude domination agreement		Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	https://www.investing.com/news/stock-market-news/ams-and-osram-conclude-domination-agreement-2303682	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams alr
5029	SIX	Swiss Exchange	Swiss Exchange	CHE	ZUGER	Zuger Kantonalbank	Zuger Kantonalbank				19960802	BanksRegional	BanksRegional	CHF	2019	Q	20190331																								51202000	0	4165500	0		22657000		3986000				18671000	191928000	0	0	96553250	458194250	554747500
11588	SIX	Swiss Exchange	Swiss Exchange	CHE	ALC	Alcon Inc.	Alcon Inc.		-		20190409	Medical Instruments & Supplies	Medical Instruments & Supplies	USD	2022	A	20221231	5193000000.0	24016000000.0								29209000000.0	2782000000.0	6750000000.0				9532000000.0						19677000000.0	29209000000.0	8717000000.0	3969000000.0		672000000.0		463000000.0		128000000.0					1217000000.0	-1865000000.0	-8000000.0		1575000000.0	980000000.0
11589	SIX	Swiss Exchange	Swiss Exchange	CHE	ALC	Alcon Inc.	Alcon Inc.		-		20190409	Medical Instruments & Supplies	Medical Instruments & Supplies	USD	2022	Q	20221231	5193000000.0	24016000000.0								29209000000.0	2782000000.0	6750000000.0				9532000000.0						19677000000.0	29209000000.0	2171000000.0	1001000000.0		9000000.0		-31000000.0		66000000.0					345000000.0	-852000000.0	281000000.0		1177000000.0	980000000.0
11590	SIX	Swiss Exchange	Swiss Exchange	CHE	ALC	Alcon Inc.	Alcon Inc.		-		20190409	Medical Instruments & Supplies	Medical Instruments & Supplies	USD	2022	Q	20220930	5163000000.0	22633000000.0								27796000000.0	2334000000.0	5815000000.0				8149000000.0						19647000000.0	27796000000.0	2140000000.0	974000000.0		205000000.0		147000000.0		31000000.0					402000000.0	-251000000.0	-12000000.0		1030000000.0	1177000000.0
870				CHE	BPDG									CHF	2018	Q	20180131																								3179722.75	0	33750	0		-17565		64894.5				-82459.5	12701250	0	0	0	0	0
11591	SIX	Swiss Exchange	Swiss Exchange	CHE	ALC	Alcon Inc.	Alcon Inc.		-		20190409	Medical Instruments & Supplies	Medical Instruments & Supplies	USD	2022	Q	20220630	5017000000.0	22710000000.0								27727000000.0	2320000000.0	5866000000.0				8186000000.0						19541000000.0	27727000000.0	2217000000.0	1013000000.0		200000000.0		147000000.0		-1000000.0					404000000.0	-159000000.0	-188000000.0		961000000.0	1030000000.0
11592	SIX	Swiss Exchange	Swiss Exchange	CHE	ALC	Alcon Inc.	Alcon Inc.		-		20190409	Medical Instruments & Supplies	Medical Instruments & Supplies	USD	2022	Q	20220331	4888000000.0	22902000000.0								27790000000.0	2247000000.0	6057000000.0				8304000000.0						19486000000.0	27790000000.0	2189000000.0	981000000.0		246000000.0		200000000.0		32000000.0					66000000.0	-603000000.0	-89000000.0		1575000000.0	961000000.0
11593	SIX	Swiss Exchange	Swiss Exchange	CHE	ALLN	Allreal Holding AG	Allreal Holding AG		-		20000303	Real Estate Services	Real Estate Services	CHF	2022	A	20221231	481300000.0	5207800000.0								5689100000.0	1076100000.0	2017100000.0				3093200000.0						2595900000.0	5689100000.0	502000000.0	260600000.0		200700000.0		184500000.0		29800000.0					159600000.0	12600000.0	-231500000.0		73400000.0	14100000.0
11594	SIX	Swiss Exchange	Swiss Exchange	CHE	ALLN	Allreal Holding AG	Allreal Holding AG		-		20000303	Real Estate Services	Real Estate Services	CHF	2022	Q	20221231	481300000.0	5207800000.0								5689100000.0	1076100000.0	2017100000.0				3093200000.0						2595900000.0	5689100000.0
11595	SIX	Swiss Exchange	Swiss Exchange	CHE	ALLN	Allreal Holding AG	Allreal Holding AG		-		20000303	Real Estate Services	Real Estate Services	CHF	2022	Q	20220630	495900000.0	5237500000.0								5733400000.0	1128400000.0	2079300000.0				3207700000.0						2525700000.0	5733400000.0
11596	SIX	Swiss Exchange	Swiss Exchange	CHE	ALPN	Alpine Select AG	Alpine Select AG		-		20110927	Asset Management	Asset Management	CHF	2022	Q	20220630	4161000.0	127469000.0								131732000.0	0.0	0.0				17343000.0						108184000.0	131732000.0
11597	SIX	Swiss Exchange	Swiss Exchange	CHE	ALSN	ALSO Holding AG	ALSO Holding AG		-		20060623	Electronics & Computer Distribution	Electronics & Computer Distribution	EUR	2022	A	20221231	2705042000.0	448475000.0								3153517000.0	1831130000.0	281974000.0				2113104000.0						1039578000.0	3153517000.0	11552876000.0	10839468000.0		236831000.0		207941000.0		55574000.0					88108000.0	-8789000.0	-225187000.0		617245000.0	478718000.0
11598	SIX	Swiss Exchange	Swiss Exchange	CHE	ALSN	ALSO Holding AG	ALSO Holding AG		-		20060623	Electronics & Computer Distribution	Electronics & Computer Distribution	EUR	2022	Q	20221231	2705042000.0	448475000.0								3153517000.0	1831130000.0	281974000.0				2113104000.0						1039578000.0	3153517000.0
11599	SIX	Swiss Exchange	Swiss Exchange	CHE	ALSN	ALSO Holding AG	ALSO Holding AG		-		20060623	Electronics & Computer Distribution	Electronics & Computer Distribution	EUR	2022	Q	20220630	2424028000.0	401107000.0								2825135000.0	1574576000.0	262243000.0				1836819000.0						987602000.0	2825135000.0
11600	SIX	Swiss Exchange	Swiss Exchange	CHE	AMS	ams-OSRAM AG	ams-OSRAM AG		-		20040517	Semiconductors	Semiconductors	EUR	2022	Q	20220930	3313000000.0	6075000000.0								9388000000.0	2646000000.0	3441000000.0				6087000000.0						3294000000.0	9381000000.0	1213000000.0	945000000.0		-326000000.0		-385000000.0		-14000000.0					151000000.0	14000000.0	-449000000.0		1450000000.0	1248000000.0
11601	SIX	Swiss Exchange	Swiss Exchange	CHE	AMS	ams-OSRAM AG	ams-OSRAM AG		-		20040517	Semiconductors	Semiconductors	EUR	2022	Q	20220630	3588000000.0	6353000000.0								9941000000.0	2868000000.0	3519000000.0				6387000000.0						3545000000.0	9932000000.0	1183000000.0	834000000.0		217000000.0		166000000.0		108000000.0					100000000.0	148000000.0	-112000000.0		1250000000.0	1450000000.0
11602	SIX	Swiss Exchange	Swiss Exchange	CHE	AMS	ams-OSRAM AG	ams-OSRAM AG		-		20040517	Semiconductors	Semiconductors	EUR	2022	Q	20220331	3268000000.0	6346000000.0								9606000000.0	2888000000.0	3480000000.0				6368000000.0						3238000000.0	9606000000.0	1246000000.0	861000000.0		39000000.0		-10000000.0		-26000000.0					147000000.0	-109000000.0	-127000000.0		1339000000.0	1235000000.0
11603	SIX	Swiss Exchange	Swiss Exchange	CHE	APGN	APG\|SGA SA	APG\|SGA SA		-		20040818	Advertising Agencies	Advertising Agencies	CHF	2022	A	20221231	108941000.0	80465000.0								189406000.0	89845000.0	8337000.0				98182000.0						91224000.0	189406000.0	310600000.0	190380000.0		29372000.0		29094000.0		5702000.0					18255000.0	-4277000.0	-32955000.0		72362000.0	53311000.0
11604	SIX	Swiss Exchange	Swiss Exchange	CHE	APGN	APG\|SGA SA	APG\|SGA SA		-		20040818	Advertising Agencies	Advertising Agencies	CHF	2022	Q	20221231	108941000.0	80465000.0								189406000.0	89845000.0	8337000.0				98182000.0						91224000.0	189406000.0
11605	SIX	Swiss Exchange	Swiss Exchange	CHE	APGN	APG\|SGA SA	APG\|SGA SA		-		20040818	Advertising Agencies	Advertising Agencies	CHF	2022	Q	20220630	92517000.0	82647000.0								175164000.0	87521000.0	9107000.0				96628000.0						78536000.0	175164000.0
11606	SIX	Swiss Exchange	Swiss Exchange	CHE	ARBN	Arbonia AG	Arbonia AG		-		20090430	Building Products & Equipment	Building Products & Equipment	CHF	2022	A	20221231	422748000.0	1096764000.0								1519512000.0	337248000.0	194722000.0				531970000.0						987542000.0	1519512000.0	1202097000.0	573630000.0		32987000.0		29818000.0		9146000.0					-25759000.0	-219789000.0	21465000.0		253870000.0	29196000.0
11607	SIX	Swiss Exchange	Swiss Exchange	CHE	ARBN	Arbonia AG	Arbonia AG		-		20090430	Building Products & Equipment	Building Products & Equipment	CHF	2022	Q	20221231	422748000.0	1096764000.0								1519512000.0	337248000.0	194722000.0				531970000.0						987542000.0	1519512000.0
11608	SIX	Swiss Exchange	Swiss Exchange	CHE	ARBN	Arbonia AG	Arbonia AG		-		20090430	Building Products & Equipment	Building Products & Equipment	CHF	2022	Q	20220630	532864000.0	1004915000.0								1537779000.0	332200000.0	189500000.0				521700000.0						1016079000.0	1537779000.0
5390	SIX	Swiss Exchange	Swiss Exchange	CHE	APGN	APG\|SGA SA	APG\|SGA SA				20040818	Advertising Agencies	Advertising Agencies	CHF	2021	A	20211231																																																20200922	Stock News			Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	https://www.investing.com/news/stock-market-news/ams-and-osram-conclude-domination-agreement-2303682	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams alr
5391	SIX	Swiss Exchange	Swiss Exchange	CHE	APGN	APG\|SGA SA	APG\|SGA SA				20040818	Advertising Agencies	Advertising Agencies	CHF	2021	Q	20211231																																																20200922	Stock News			Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	https://www.investing.com/news/stock-market-news/ams-and-osram-conclude-domination-agreement-2303682	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams already owns 71% of Osram.▦The domination agreement foresees an offer to buy out outside shareholders at 44.65 euros per share. It also contains annual recurring compensation of 2.24 euros.▦Osram shares closed on Tuesday at 43.40 euros.	Reuters. The Logo of Austrian sensor specialist AMS is seen on their factory in Unterpremstaetten▦ OSRn▦0.00%▦AMS▦-3.53%▦BERLIN (Reuters) - Austrian sensor maker ams (VI:AMS) said on Tuesday it had signed a so-called domination and profit and loss transfer agreement (DPLTA) with Osram (DE:OSRn) in a key step towards closing out its 4.6 billion euro ($5.4 billion) takeover of the German firm.▦Implementing the agreement will enable the swift and successful integration of ams and Osram into a combined company that offers profitable growth for the long term ams CEO Alexander Everke said in a statement.▦To take effect the agreement will require the support of 75% of shareholders at an extraordinary general meeting planned on Nov. 3. Ams alr
11609	SIX	Swiss Exchange	Swiss Exchange	CHE	ARON	Arundel AG	Arundel AG		-		20050719	Capital Markets	Capital Markets	USD	2022	Q	20220630	6033200.0	185393324.0								191426524.0	13405448.0	166179298.0				179584746.0						8577304.0	191426524.0
11610	SIX	Swiss Exchange	Swiss Exchange	CHE	ARYN	ARYZTA AG	ARYZTA AG		-		20080822	Packaged Foods	Packaged Foods	EUR	2023	Q	20230131	498400000.0	1527300000.0								2025700000.0	572300000.0	500100000.0				1072400000.0						953300000.0	2025700000.0
11611	SIX	Swiss Exchange	Swiss Exchange	CHE	ARYN	ARYZTA AG	ARYZTA AG		-		20080822	Packaged Foods	Packaged Foods	EUR	2022	A	20220731	521600000.0	1561000000.0								2082600000.0	520600000.0	629600000.0				1150200000.0						932400000.0	2082600000.0	1756100000.0	1205800000.0		91400000.0		22700000.0		20800000.0					200100000.0	8900000.0	-143400000.0		170900000.0	245800000.0
11612	SIX	Swiss Exchange	Swiss Exchange	CHE	ARYN	ARYZTA AG	ARYZTA AG		-		20080822	Packaged Foods	Packaged Foods	EUR	2022	Q	20220731	521600000.0	1561000000.0								2082600000.0	520600000.0	629600000.0				1150200000.0						932400000.0	2082600000.0
727	SIX	Swiss Exchange	Swiss Exchange	CHE	BELL	Bell Food Group AG	Bell Food Group AG				19960802	Packaged Foods	Packaged Foods	CHF	2018	Q	20180331																																				80925000	0	0	39950000	20750000	60700000
768				CHE	BLIN									CHF	2018	Q	20181231	9582000	408036000	1805000					0	0	417618000	110731000	147028000			0	257759000				0	145947000	159859000	417618000
11613	SIX	Swiss Exchange	Swiss Exchange	CHE	ARYN	ARYZTA AG	ARYZTA AG		-		20080822	Packaged Foods	Packaged Foods	EUR	2022	Q	20220131	458400000.0	1525800000.0								1984200000.0	453100000.0	577200000.0				1030300000.0						953900000.0	1984200000.0
11614	SIX	Swiss Exchange	Swiss Exchange	CHE	ARYN	ARYZTA AG	ARYZTA AG		-		20080822	Packaged Foods	Packaged Foods	EUR	2022	Q	20210930	129675000.0	386250000.0								515925000.0	167500000.0	72900000.0				240400000.0						275525000.0	515925000.0	381350000.0	264625000.0		-3150000.0		-9200000.0		3375000.0					29225000.0	6800000.0	-238175000.0		105900000.0	42725000.0
11615	SIX	Swiss Exchange	Swiss Exchange	CHE	ASCN	Ascom Holding AG	Ascom Holding AG		-		20001108	Health Information Services	Health Information Services	CHF	2022	A	20221231	155300000.0	46500000.0								201800000.0	89900000.0	38500000.0				128400000.0						73400000.0	201800000.0	297400000.0	161300000.0		14000000.0		14900000.0		3900000.0					10200000.0	-14000000.0	2200000.0		29500000.0	26600000.0
11616	SIX	Swiss Exchange	Swiss Exchange	CHE	ASCN	Ascom Holding AG	Ascom Holding AG		-		20001108	Health Information Services	Health Information Services	CHF	2022	Q	20221231	155300000.0	46500000.0								201800000.0	89900000.0	38500000.0				128400000.0						73400000.0	201800000.0
11617	SIX	Swiss Exchange	Swiss Exchange	CHE	ASCN	Ascom Holding AG	Ascom Holding AG		-		20001108	Health Information Services	Health Information Services	CHF	2022	Q	20220630	132400000.0	45800000.0								178200000.0	85700000.0	27300000.0				113000000.0						65200000.0	178200000.0
11618	SIX	Swiss Exchange	Swiss Exchange	CHE	ASWN	Asmallworld AG	Asmallworld AG		-		20180320	Travel Services	Travel Services	CHF	2022	A	20221231	6481500.0	5820600.0								12302100.0	5916600.0	8589700.0				14506300.0						-2204200.0	12302100.0	18454700.0	10721000.0		1824700.0		1595800.0		142400.0					2334200.0	-7236500.0	3702500.0		5226000.0	4013600.0
11619	SIX	Swiss Exchange	Swiss Exchange	CHE	ASWN	Asmallworld AG	Asmallworld AG		-		20180320	Travel Services	Travel Services	CHF	2022	Q	20221231	6481500.0	5820600.0								12302100.0	5916600.0	8589700.0				14506300.0						-2204200.0	12302100.0
11620	SIX	Swiss Exchange	Swiss Exchange	CHE	ASWN	Asmallworld AG	Asmallworld AG		-		20180320	Travel Services	Travel Services	CHF	2022	Q	20220630	5151700.0	5941900.0								11093600.0	4808800.0	9056900.0				13865700.0						-2772100.0	11093600.0
11621	SIX	Swiss Exchange	Swiss Exchange	CHE	AUTN	Autoneum Holding AG	Autoneum Holding AG		-		20110513	Auto Parts	Auto Parts	CHF	2022	A	20221231	605500000.0	866400000.0								1471900000.0	497900000.0	542000000.0				1039900000.0						339100000.0	1471900000.0	1804500000.0	878100000.0		29300000.0		15700000.0		4700000.0					94500000.0	-37200000.0	-30400000.0		103700000.0	123600000.0
11622	SIX	Swiss Exchange	Swiss Exchange	CHE	AUTN	Autoneum Holding AG	Autoneum Holding AG		-		20110513	Auto Parts	Auto Parts	CHF	2022	Q	20221231	605500000.0	866400000.0								1471900000.0	497900000.0	542000000.0				1039900000.0						339100000.0	1471900000.0
11623	SIX	Swiss Exchange	Swiss Exchange	CHE	AUTN	Autoneum Holding AG	Autoneum Holding AG		-		20110513	Auto Parts	Auto Parts	CHF	2022	Q	20220630	629000000.0	904000000.0								1532900000.0	610000000.0	480800000.0				1090800000.0						342300000.0	1532900000.0
5207	SIX	Swiss Exchange	Swiss Exchange	CHE	ADXN	Addex Therapeutics Ltd	Addex Therapeutics Ltd				20070522	Biotechnology	Biotechnology	CHF	2019	Q	20190930																																																20090914	Stock News	Addex lead drug shows potential in Parkinson's		MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	https://www.investing.com/news/equities-news/addex-lead-drug-shows-potential-in-parkinson's-86363	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive
1207				CHE	COMD									EUR	2019	Q	20191231	29684623000	73887000	25099229000					30544000	0	29758510000	0	0			28990070000	28990070000				-61568000	394796000	768440000	29758510000	91378000	0	73714000	0		14941000		3437000				10178000
5212	SIX	Swiss Exchange	Swiss Exchange	CHE	ADXN	Addex Therapeutics Ltd	Addex Therapeutics Ltd				20070522	Biotechnology	Biotechnology	CHF	2018	Q	20180630																																																20090914	Stock News	Addex lead drug shows potential in Parkinson's		MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	https://www.investing.com/news/equities-news/addex-lead-drug-shows-potential-in-parkinson's-86363	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive evidence that ADX10059 has the potential to lower side effects from levodopa treatment of mid- to late-stage Parkinson's disease patients said Olav Zilian analyst at Swiss brokerage Helvea.▦The development programme on AD10059 is the main driver of our valuation and contributes some 85 percent to our fair value of Addex said Zilian who has a buy recommendation and price target of 59 Swiss francs on the stock.▦Addex shares rose 5.3 percent to 31.95 francs by 1130 GMT versus a slightly lower overall DJ Stoxx European healthcare index.▦The group has two partnering deals with Merck & Co Inc in schizoprenia and Parkinson's disease. A third agreement with Johnson & Johnson focuses on developing drugs to treat anxiety and schizophrenia.▦A second Swiss biotech company Santhera last month struck a deal with Canada's Biovail over a drug to treat dyskinesia in Parkinson's disease. (Reporting by Sam Cage; Editing by Jon Loades-Carter)	MRK▦-0.03%▦* Reduced dyskinesia in study with primates▦* Shares rise more than 5 percent▦ZURICH Sept 14 (Reuters) - Swiss biotech Addex's lead drug candidate showed potential to treat a complication of Parkinson's disease in a study with non-human primates news of which boosted the group's shares.▦Two different doses of ADX10059 significantly reduced dyskinesia the sudden uncontrollable and often chaotic movements of limbs face tongue and body that are induced by extended use of standard therapy levodopa.▦Addex which does not yet have a drug on the market said ADX10059 will soon complete Phase IIb clinical testing in gastroesophageal reflux disease (GERD) and migraine prevention.▦We welcome today's news flow as it provides strong supportive
1002	SIX	Swiss Exchange	Swiss Exchange	CHE	CALN	CALIDA Holding AG	CALIDA Holding AG				20110418	Apparel Manufacturing	Apparel Manufacturing	CHF	2017	Q	20170331																								95158500	34259500	6499250	5397750		5374250		1156500				3833000	7756250	0	0	1245000	10055000	11300000
11624	SIX	Swiss Exchange	Swiss Exchange	CHE	BAER	Julius Br Gruppe AG	Julius Br Gruppe AG		-		20091001	Asset Management	Asset Management	CHF	2022	Q	20220630	26234800000.0	34874300000.0								115835200000.0	0.0	0.0				109747500000.0						6084400000.0	115835200000.0
11625	SIX	Swiss Exchange	Swiss Exchange	CHE	BALN	Bloise Holding AG	Bloise Holding AG		-		20010724	InsuranceDiversified	InsuranceDiversified	CHF	2022	A	20221231	30884600000.0	50515800000.0								80550100000.0	746700000.0	746700000.0				75998000000.0						4539500000.0	80550100000.0	7447100000.0	0.0		720400000.0		682900000.0		138400000.0					-388000000.0	-74300000.0	-155800000.0		4073500000.0	3370200000.0
11626	SIX	Swiss Exchange	Swiss Exchange	CHE	BALN	Bloise Holding AG	Bloise Holding AG		-		20010724	InsuranceDiversified	InsuranceDiversified	CHF	2022	Q	20221231	30884600000.0	50515800000.0								80550100000.0	746700000.0	746700000.0				75998000000.0						4539500000.0	80550100000.0
11627	SIX	Swiss Exchange	Swiss Exchange	CHE	BALN	Bloise Holding AG	Bloise Holding AG		-		20010724	InsuranceDiversified	InsuranceDiversified	CHF	2022	Q	20220630	33363200000.0	53873700000.0								83730800000.0	855200000.0	855200000.0				78709800000.0						5006200000.0	83730800000.0
11628	SIX	Swiss Exchange	Swiss Exchange	CHE	BANB	Bachem Holding AG	Bachem Holding AG		-		20010629	Chemicals	Chemicals	CHF	2022	A	20221231	760420000.0	623449000.0								1383869000.0	164780000.0	49428000.0				214208000.0						1169661000.0	1383869000.0	531741000.0	360462000.0		127224000.0		112074000.0		11390000.0					92648000.0	-63151000.0	-87006000.0		89191000.0	31451000.0
11629	SIX	Swiss Exchange	Swiss Exchange	CHE	BANB	Bachem Holding AG	Bachem Holding AG		-		20010629	Chemicals	Chemicals	CHF	2022	Q	20221231	760420000.0	623449000.0								1383869000.0	164780000.0	49428000.0				214208000.0						1169661000.0	1383869000.0

연락처및 데이터권한 정보1
판매제공처 홈페이지	www.hebronstar.com	라이선스	Creative Commons Attribution
판매 담당자	헤브론스타	권한	Copyright 2022 ⓒ Hebronstar All Right Reserved.
연락처	070-4438-9587	접근 권한	public
이메일	info@hebronstar.com	상품 구분	dataset

연락처및 데이터권한 정보2
품질측정 검사		품질측정기간	~
품질측정기관	헤브론스타	품질측정연락정보	024179322
품질측정결과		품질측정내용

제약 및 취소/환불 규정 안내

데이터 상품은 디지털화된 상품의 특성상 반품, 취소, 환불 되지 않으나 데이터의 심각한 오류 또는, 상이한 데이터인 경우 구매자가 요구 시 환불을 진행할 수 있습니다.

현재 준비중입니다.

서브 페이지 본문 시작

데이터 마켓